Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | G6PD | P11413 | 1/20 | 0.49 |
| ▸ | PYGB | P11216 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13576889 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL14421703 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL136446 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL166332 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL14898436 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL12304019 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL50473 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL21847893 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL20745165 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL10307315 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| EP-3434684-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | Keio University (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-20180111955-A1 | THIOSACCHARIDE MUCOLYTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| US-9856283-B2 | Thiosaccharide mucolytic agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-02 | — | — | US | disclosed |
| WO-2017163808-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | 学校法人慶應義塾 | 2017-09-28 | — | — | WO | disclosed |
| US-9717790-B2 | Sphingoglycolipid analogues | VICTORIA LINK LIMITED (NZ) | 2017-08-01 | — | — | US | disclosed |
| US-9717790-B2 | Sphingoglycolipid analogues | VICTORIA LINK LIMITED (NZ) | 2017-08-01 | — | — | US | disclosed |
| US-9586985-B2 | Organic compounds as proantigens for natural killer T cells | VICTORIA LINK LIMITED (NZ) | 2017-03-07 | — | — | US | disclosed |
| US-20160136267-A1 | SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2016-05-19 | — | — | US | disclosed |
| US-20160136267-A1 | SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2016-05-19 | — | — | US | disclosed |
| US-20160060284-A1 | THIOSACCHARIDE MUCOLYTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-03 | — | — | US | disclosed |
| US-20160060284-A1 | THIOSACCHARIDE MUCOLYTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-03 | — | — | US | disclosed |
| US-20150191503-A1 | ORGANIC COMPOUNDS | VICTORIA LINK LIMITED (NZ) | 2015-07-09 | — | — | US | disclosed |
| WO-2014200363-A1 | SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014153009-A2 | THIOSACCHARIDE MUCOLYTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8551959-B2 | Glycolipid and use thereof | RIKEN (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551959-B2 | Glycolipid and use thereof | RIKEN (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8299223-B2 | Pseudoglycolipid and use thereof | RIKEN (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110104188-A1 | NOVEL GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20100062990-A1 | NOVEL PSEUDOGLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104188-A1 | NOVEL GLYCOLIPID AND USE THEREOF | SGMS1, UGCG, SGPL1 | L3MBTL1 2364/4885MAPT 4438/4885LGALS8 108/4885 |
| US-20180111955-A1 | THIOSACCHARIDE MUCOLYTIC AGENTS | MUC1, TREH, FUT6 | L3MBTL1 3570/4885MAPT 4252/4885LGALS8 109/4885 |
| US-20160136267-A1 | SPHINGOGLYCOLIPID ANALOGUES | UGCG, SGPL1, SMPD2 | L3MBTL1 609/4885MAPT 3433/4885LGALS8 156/4885 |
| US-20160060284-A1 | THIOSACCHARIDE MUCOLYTIC AGENTS | MUC1, TREH, FUT6 | L3MBTL1 3570/4885MAPT 4252/4885LGALS8 109/4885 |
| US-20150191503-A1 | ORGANIC COMPOUNDS | SGMS1, UGCG, SGMS2 | L3MBTL1 894/4885MAPT 1967/4885LGALS8 185/4885 |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | L3MBTL1 860/4885MAPT 199/4885LGALS8 2516/4885 |
| US-20100062990-A1 | NOVEL PSEUDOGLYCOLIPID AND USE THEREOF | PNLIP, SGMS1, SGPL1 | L3MBTL1 879/4885MAPT 4600/4885LGALS8 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.